GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Stromacel PROT · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2011

Revenue

$26,004

FY2011FY2011

Net income

−$1.4m

FY2011FY2011

Free cash flow

−$277,210

FY2011FY2011

Shareholders' equity

−$3.7m

FY2011FY2011

Income statement

Fiscal years

FY2011
Revenue$26,004
Gross profit$26,517
Research and development$530,647
Operating income−$1.3m
Net income−$1.4m
Diluted earnings per share-0.21

Balance sheet

At each fiscal year end

FY2011
Total assets$3.3m
Total liabilities$7.0m
Shareholders' equity−$3.7m
Shares outstanding7m

Cash flow

Fiscal years

FY2011
Cash from operations−$277,210
Free cash flow−$277,210

Latest quarters

By quarter end

Jun 2012Mar 2012Dec 2011Sept 2011Jun 2011Mar 2011Dec 2010Sept 2010
Revenue—$2,290$7,010$7,015——$10,000$20,000
Gross profit—$1,705$45,444−$23,745———$20,000
Operating income−$757,654−$2.2m−$393,406−$378,982−$239,400−$260,000−$1.1m−$610,000
Net income$1.4m−$2.2m−$410,314−$399,862−$274,200−$300,000−$1.1m−$610,000
Diluted earnings per share0.18-0.16-0.21-0.06-0.04-0.05-0.23-0.13
Total assets$5.8m$7.0m$3.3m$3.4m$3.5m$3.6m$3.6m$3.8m
Cash and short-term investments————$500———
Shareholders' equity−$1,685$356,052−$3.7m−$3.6m−$3.4m−$3.3m−$3.4m−$2.5m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-41.8%-32.3%-48.8%
Operating income-35.4%2.3%-0.0%
Net income-34.7%3.6%-1.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin86.0%85.4%85.8%14.8%
Operating margin-4351.4%-3506.9%-2828.3%-106.6%
Net margin-4439.9%-3572.1%-2873.5%-96.5%

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return900%0%-90%0%6613%422421%7945%1403%2575%38%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 21 Aug 2008
  • 37-to-1 reverse split · 3 Oct 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.